November 14, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.11.006

First-cycle β-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia.

Listen to this summary

This retrospective study of 299 low-risk gestational trophoblastic neoplasia patients asked whether the ratio of β-hCG levels before cycle 2 to before cycle 1 (C2/C1) can predict resistance to first-line single-agent chemotherapy. Using a threshold of 0.38, a first-cycle dynamic model incorporating this ratio outperformed a baseline clinical model in both development and internal validation cohorts (AUCs 0.867 and 0.844), with chemoresistance rates of roughly 44% in poor responders versus about 9% in favorable responders. Although the findings suggest the marker could help identify patients needing closer monitoring, prospective multicenter validation is still required.

Yan Wang, Yan Kong, Yanci Che, Xinyue Luan, Xiao Li, Zhumei Cui, Tian Tian

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play